Digestive Diseases and Sciences

, Volume 59, Issue 8, pp 1754–1763 | Cite as

miR-1303 Targets Claudin-18 Gene to Modulate Proliferation and Invasion of Gastric Cancer Cells

  • Shi-jie Zhang
  • Jian-fang Feng
  • Lei Wang
  • Wei Guo
  • Yu-wen Du
  • Liang Ming
  • Guo-qiang ZhaoEmail author
Original Article



MicroRNAs have emerged as important gene regulators and are recognized as important molecules in carcinogenesis. However, the effects of microRNA-1303 (miR-1303) on gastric cancer (GC) cells and the upstream regulation of GC-associated claudin-18 gene (CLDN18) remain unclear. miR-1303 may be involved in the tumorigenesis of GC by targeting CLDN18.


The purpose of this study was to explore the effect of miR-1303 targeting of CLDN18 on the proliferation, migration and invasion of human GC cells.


The expression of miR-1303 and claudin-18 in GC tissues and gastric cancer cell lines were detected by qRT-PCR and western blotting, respectively. CCK8 and colony formation assays were performed to study the influence of miR-1303 on the proliferation of the GC cell lines. Transwell and wound-healing assays were carried out to investigate the effect of miR-1303 on the invasion and migration of GC cell lines. Luciferase reporter assays, restore assays and western blotting were used to demonstrate whether CLDN18 is a direct target of miR-1303.


miR-1303 was significantly overexpressed whereas claudin-18 was downregulated in GC tissues and cell lines, which was significantly associated with tumor size, location invasion, histologic type and tumor-node-metastasis stage. Cell proliferation rates were reduced, and cell invasion and migratory ability was significantly restricted in miR-1303 inhibitor-transfected groups. miR-1303 could bind to the putative binding sites in CLDN18 mRNA 3′-UTR and visibly lower the expression of claudin-18. The introduction of claudin-18 without 3′-UTR restored the miR-1303 promoting migration function.


Downregulation of miR-1303 can inhibit proliferation, migration and invasion of GC cells by targeting CLDN18.


miR-1303 Claudin-18 Stomach neoplasms Proliferation Invasion 


Conflict of interest



  1. 1.
    Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.PubMedCrossRefGoogle Scholar
  3. 3.
    Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–362.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Zheng L, Wang L, Ajani J, et al. Molecular basis of gastric cancer development and progression. Gastric Cancer. 2004;7:61–77.PubMedCrossRefGoogle Scholar
  5. 5.
    Ebert MP, Fei G, Kahmann S, et al. Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis. 2002;23:87–91.PubMedCrossRefGoogle Scholar
  6. 6.
    Tamura G, Yin J, Wang S, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst. 2000;92:569–573.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854.PubMedCrossRefGoogle Scholar
  8. 8.
    Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75:855–862.PubMedCrossRefGoogle Scholar
  9. 9.
    Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks. J Mol Biol. 2013;425:3582–3600.PubMedCrossRefGoogle Scholar
  10. 10.
    Farazi TA, Hoell JI, Morozov P, et al. MicroRNAs in human cancer. Adv Exp Med Biol. 2013;774:1–20.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Fabbri M. MicroRNAs and cancer: towards a personalized medicine. Curr Mol Med. 2013;13:751–756.PubMedCrossRefGoogle Scholar
  12. 12.
    Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.PubMedCrossRefGoogle Scholar
  13. 13.
    Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006;6:186.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Ouban A, Ahmed AA. Claudins in human cancer: a review. Histol Histopathol. 2010;25:83–90.PubMedGoogle Scholar
  15. 15.
    Turksen K. Claudins and cancer stem cells. Stem Cell Rev.. 2011;7:797–798.PubMedCrossRefGoogle Scholar
  16. 16.
    Iravani O, Tay BW, Chua PJ, et al. Claudins and gastric carcinogenesis. Exp Biol Med.. 2013;238:344–349.CrossRefGoogle Scholar
  17. 17.
    Németh Z, Szász AM, Tátrai P, et al. Claudin-1, -2, -3, -4, -7, -8, and -10 protein expression in biliary tract cancers. J Histochem Cytochem. 2009;57:113–121.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Szász M. Claudins as prognostic factors of breast cancer. Magy Onkol.. 2012;56:209–212.PubMedGoogle Scholar
  19. 19.
    Lechpammer M, Resnick MB, Sabo E, et al. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod Pathol. 2008;21:1320–1329.PubMedCrossRefGoogle Scholar
  20. 20.
    Niimi T, Nagashima K, Ward JM, et al. Claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol. 2001;21:7380–7390.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Sanada Y, Oue N, Mitani Y, et al. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol.. 2006;208:633–642.PubMedCrossRefGoogle Scholar
  22. 22.
    Matsuda Y, Semba S, Ueda J, et al. Gastric and intestinal claudin expression at the invasive front of gastric carcinoma. Cancer Sci. 2007;98:1014–1019.PubMedCrossRefGoogle Scholar
  23. 23.
    Jang BG, Kim WH. Molecular pathology of gastric carcinoma. Pathobiology. 2011;78:302–310.PubMedCrossRefGoogle Scholar
  24. 24.
    Oshima T, Shan J, Okugawa T, et al. Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front. PLoS ONE. 2013;8:e74757.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Ayaz L, Görür A, Yaroğlu HY, et al. Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol. 2013;139:1499–1506.PubMedCrossRefGoogle Scholar
  26. 26.
    El-Murr N, Abidi Z, Wanherdrick K, et al. MiRNA genes constitute new targets for microsatellite instability in colorectal cancer. PLoS ONE. 2012;7:e31862.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Maurel M, Jalvy S, Ladeiro Y, et al. A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma. Hepatology. 2013;57:195–204.PubMedCrossRefGoogle Scholar
  28. 28.
    Xi JJ. MicroRNAs in cancer. Cancer Treat Res. 2013;158:119–137.PubMedCrossRefGoogle Scholar
  29. 29.
    Li X, Zhang Y, Zhang Y, et al. Survival prediction of gastric cancer by a seven-microRNA signature. Gut. 2010;59:579–585.PubMedCrossRefGoogle Scholar
  30. 30.
    Yao Y, Suo AL, Li ZF, et al. MicroRNA profiling of human gastric cancer. Mol Med Rep.. 2009;2:963–970.PubMedGoogle Scholar
  31. 31.
    Brenner B, Hoshen MB, Purim O, et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol. 2011;17:3976–3985.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Yan Z, Xiong Y, Xu W, et al. Identification of recurrence-related genes by integrating microRNA and gene expression profiling of gastric cancer. Int J Oncol. 2012;41:2166–2174.PubMedGoogle Scholar
  33. 33.
    Tong F, Cao P, Yin Y, et al. MicroRNAs in gastric cancer: from benchtop to bedside. Dig Dis Sci. 2014;59:24–30.PubMedCrossRefGoogle Scholar
  34. 34.
    Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624–7634.PubMedCrossRefGoogle Scholar
  35. 35.
    Türeci O, Koslowski M, Helftenbein G, et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 2011;481:83–92.PubMedCrossRefGoogle Scholar
  36. 36.
    Tanaka M, Shibahara J, Fukushima N, et al. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem. 2011;59:942–952.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Lerebours F, Cizeron-Clairac G, Susini A, et al. miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness. Int J Cancer. 2013;133:1614–1623.PubMedCrossRefGoogle Scholar
  38. 38.
    Hansen TB, Kjems J, Bramsen JB. Enhancing miRNA annotation confidence in miRBase by continuous cross dataset analysis. RNA Biol. 2011;8:378–383.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Shi-jie Zhang
    • 1
  • Jian-fang Feng
    • 2
  • Lei Wang
    • 3
  • Wei Guo
    • 4
  • Yu-wen Du
    • 5
  • Liang Ming
    • 1
  • Guo-qiang Zhao
    • 5
    Email author
  1. 1.Department of Clinical LaboratoryThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  2. 2.Medical College of Henan University of Science and TechnologyLuoyangChina
  3. 3.Department of EmergencyThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  4. 4.Henan Academy of Medical and Pharmaceutical SciencesZhengzhou UniversityZhengzhouChina
  5. 5.College of Basic Medical SciencesZhengzhou UniversityZhengzhouChina

Personalised recommendations